Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials

Androgen deprivation therapy (ADT) is an effective, commonly used treatment in localised prostate cancer [1]. In the National Comprehensive Cancer Network guidelines Version 1.2024 [2], the recommendation of ADT plus radiotherapy (RT) for unfavorable intermediate risk prostate cancer (IRPC) is listed as category 2a evidence and as category 1 evidence for high-risk prostate cancer (HRPC). However, ADT is also associated with a long list of hypogonadal side effects that significantly affect patients ’ quality of life [3], including hot flashes [4], fatigue [5], anemia [6], decrease muscle strength, increase body fat [7,8]depression, anxiety [9,10], metabolic syndromes [11], decrease penile and testicular size [12], sexual dysfunction [13,14], increase of cardiovascular risk [15], osteoporosis and bone fractures [16–19].

Source: Radiotherapy and Oncology - March 27, 2024 Category: Radiology Authors: Abdenour Nabid, Nathalie Carrier, Andr é-Guy Martin, Eric Vigneault, Jean-Paul Bahary, Thu Van Nguyen, Peter Vavassis, Sylvie Vass, Marc-André Brassard, Boris Bahoric, Robert Archambault, François Vincent, Redouane Bettahar, Marie Duclos, Derek Wilke, Tags: Original Article Source Type: research